EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...

EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...